Roche announced this morning that its head of pharmaceuticals, Bill Anderson, is leaving the company to pursue "other opportunities" after four years in the role. Anderson will be replaced in the ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.

Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate Nonetheless, Roche’s pharma chief Teresa Graham put Itovebi’s peak sales potential at 2 billion Swiss ...

CNBC's Angelica Peebles talks to Roche Pharma CEO Teresa Graham discusses why we're still in the early stages of the obesity drug race. Moss Landing fire: One of the world’s largest battery ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...